MDACC Study No:2009-0292 ( NCT No: NCT00992030)
Title:Phase III Study Comparing Rituximab-supplemented ABVD (R-ABVD) with ABVD Followed by Involved-field Radiotherapy (ABVD-RT) in LIMITED-stage (STAGE IA-IB-IIA WITH NO AREAS OF BULK) Hodgkin’s Lymphoma.
Principal Investigator:Michelle A. Fanale
Treatment Agent:Adriamycin; Bleomycin; Dacarbazine; Rituximab; Vincristine Sulfate
Study Status:Closed
Study Description:The combination of the drugs Adriamycin (doxorubicin), bleomycin, vinblastine,
and dacarbazine is commonly referred to as ABVD.

The goal of this clinical research study is to compare the combination of
rituximab and ABVD (R-ABVD) to the combination of ABVD and radiotherapy
(ABVD+RT) when given to patients with Hodgkin's lymphoma. The safety of these
2 treatments will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase III
Treatment Agents:Adriamycin
Vincristine Sulfate
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:Genentech
Return Visit:Pre-treatment; C1 Day 1, day 15; C1 Days 8, 22 and 36; C 2 Day 1, day 15; C 3
Day 1;C 4 Day 1, Day 15; Evaluation after Chemotherapy; Evaluation after RT;
Follow up; Every 3 mths 1st yr; Every 4 mths 2nd yr; Every 6 mths yrs 3-5; once
yr thereafter
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michelle A. Fanale
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults